AK138D1 / Akesobio - LARVOL DELTA

A Study of AK138D1 in Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Akeso

New P1 trial • Oncology • Solid Tumor

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for “IO 2.0 + ADC“ Strategy (PRNewswire) - "Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate), is Akeso's first ADC drug to enter clinical studies."

Trial status • Solid Tumor

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Akeso

Metastases • New P1 trial • Oncology • Solid Tumor

Kangfang's semi-annual report: the first self-developed ADC surfaced [Google translation] (Sina Corp) - "Another highlight in the semi-annual report is that Kangfang announced its first self-developed ADC candidate drug AK138D1-an IND application has been submitted to CDE for the treatment of advanced malignant tumors....It is expected that in the second half of this year, AK138D1 will enter the Phase I clinical dose escalation."

New P1 trial • Oncology • Solid Tumor